The HHS Office of Inspector General (OIG) has released another in its series of reports comparing Medicare average sales prices (ASPs) for Part B drugs with average manufacturer prices (AMPs). In this latest report, the OIG identified 26 drug HCPCS codes with ASP that exceeded AMP by at least 5% in the third quarter of 2009. If reimbursement amounts for these 26 codes had been based on 103% of the AMP (as is authorized by the statute), Medicare expenditures would have been reduced by $2.7 million during the first quarter of 2010. The OIG could not compare data for an additional 66 codes because AMP data were not submitted, even though manufacturers for many of those drugs had Medicaid drug rebate agreements requiring the submission of AMPs. The OIG notes that it will continue to work with CMS to evaluate and pursue appropriate actions against manufacturers that fail to submit required data.